Parkinson's disease

Neurobiology of Disease

Volumn , Issue , 2007, Pages 51-67

  Gálvez Jiménez, Néstor ^a  

^a FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70049116997     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088592-3/50007-4     Document Type: Chapter

References (92)

1. Parkinson J. An Essay on the Shaking Palsy 1817, Sherwood, Neely, & Jones, London.
2. Goetz C.G. Charcot, the Clinician: The Tuesday Lessons 1987, Raven Press, New York.
3. Sweeney P.J., Lloyd M.F., Daroff R.B. What's in a name? Dr. Lewey and the Lewy body. Neurology 1997, 49:629-630.
4. Kinkier Wilson S.A. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912, 34(4):295-309.
5. Denny-Brown D. The Cerebral Control of Movement 1966, Liverpool University Press, Liverpool.
6. Denny-Brown D. The Basal Ganglia and Their Relationship to Disorders of Movement 1962, Oxford University Press, London.
7. Denny-Brown D. Disease of the Basal Ganglia and Subtha- lamic Nuclei 1946, Oxford University Press, New York.
8. Ehringer H., Hornykiewicz O. Veteilung von nora-drenalin und dopamine (3-hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen system. Klin. Wochenschr. 1960, 38:1236-1239.
9. Birkmayer W., Hornykiewicz O. Der l-3,4-Dioxyphenylalanin (l-DOPA) -Effekt bei der Parkinson-Akinese. Wien. Klin. Wochenschr. 1961, 73:787-788.
10. Cotzias G.C. Levodopa in the treatment of parkinsonism. JAMA 1971, 218:1903-1908.
11. Burns R.S., LeWitt P.A., Ebert M.H., Pakkenberg H., Kopin I.J. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropydine (MPTP). N. Engl. J. Med. 1985, 312:1418-1421.
12. Cooper I.S. Parkinsonism. Its Medical and Surgical Therapy 1961, Charles C. Thomas, Springfield, IL.
13. Svennilson E., Torvik A., Lowe R., Leksell L. Treatment of parkinsonism by stereotactic thermolesions in the pallidal region. Acta Psychiatr. Scand. 1960, 35:358-377.
14. Lang A.E., Lozano A.M. Medical progress: Parkinson's disease. N Engl. J. Med. 1988, 339:1044-1053.
15. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., Dillon S., Winfield H., Culver S., Trojanowski J.Q., Eidelberg D., Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl. J. Med. 2001, 344:710-719.
16. Galvez-Jimenez N., Lang A.E. The perioperative management of Parkinson's disease revisited. Neurol. Clin. North Am. 2004, 22:367-377.
17. Zhang Z.X., Roman G.C., Hong Z., Wu C.B., Qu Q.M., Huang J.B., Zhou B., Geng Z.P., Wu J.X., Wen H.B., Zhao H., Zahner G.E. Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 2005, 365(9459):595-596.
18. Poewe W.H., Wenning G.K. The natural history of Parkinson's disease. Neurology 1996, 47:S146-S152.
19. Bower J.H., Maraganore D.M., McDonnell S.K., Rocca W.A. Influence of strict, intermediate, and broad diagnostic criteria on the age-and sex-specific incidence of Parkinson's disease. Mov. Disord. 2000, 15:819-825.
20. von Campenhausen S., Bornschein B., Wick R., Botzel K., Sampalo C., Poewe W., Oertel W., Siebert U., Berger K., Dodel R. Prevalence and incidence of Parkinson's disease in Europe. Eur. Neuropsychopharmacol. 2005, 15:473-490.
21. Marras C., McDermott M.P., Rochon P.A., Tanner C.M., Naglie G., Rudolph A., Lang A.E., Parkinson Study Group. Survival in Parkinson's disease. Thirteen-year follow-up of the DATATOP cohort. Neurology 2005, 64:87-93.
22. Yamada T., Hattori H., Miura A., Tanabe M., Yamori Y. Prevalence of Alzheimer's disease, vascular dementia and dementia with Lewy bodies in a Japanese population. Psychiatry Clin. Neurosci. 2001, 55:21-25.
23. Shergill S., Mullan E., D'ath P., Katona C. What is the clinical prevalence of Lewy body dementia. Int. Geriatr. Psychiatry 1994, 8:571-576.
24. Prayson R.A. Neuropathology Review 2001, Humana Press, Totowa, NJ.
25. Greenfield's Neuropathology 2002, Arnold, London. 7th edition. D.I. Graham, P.L. Lantos, (Eds.).
26. Fedorow H., Tribl F., Halliday G., Gerlach M., Riederer P., Double K.L. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Progr. Neurobiol. 2005, 75:109-124.
27. Poon H.F., Frasier M., Shreve N., Calabrese V., Wolozin B., Butterfield D.A. Mitochondrial associated metabolic proteins are selectively oxidized in A30P α-synuclein transgenic mice-a model of familial Parkinson's disease. Neurobiol. Dis. 2005, 18:492-498.
28. Lo Bianco C., Ridet J.L., Schneider B.L., Deglon N., Aebischer P. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 2002, 99:10813-10818.
29. Elkon H., Don J., Melamed E., Ziv I., Shirvan A., Offen D. Mutant-and wild-type alpha-synuclein interact with mitochon-drial cytochrome c oxidase. J. Mol. Neurosci. 2002, 18:229-238.
30. Giasson B.I., Forman M.S., Higuchi M., Golbe L.I., Graves C.L., Kotzbauer P.T., Trojanowski J.Q., Lee V.M. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003, 300:636-640.
31. Mamah C.E., Lesnick T.G., Lincoln S.J., Strain K.J., de Andrade M., Bower J.H., Ahiskog J.E., Rocca W.A., Farrer M.J., Maraganore D.M. Interaction of α-synuclein and tau genotypes in Parkinson's disease. Ann. Neurol. 2005, 57:439-443.
32. Crowther R.A., Daniel S.E., Goedert M. Charac-terization of isolated α-synuclein filaments from substantia nigra of Parkinson's disease brain. Neurosci. Lett. 2000, 292:128-130.
33. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., Mandel R.J., Bjorklund A. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 2002, 22:2780-2791.
34. Ishizawa T., Mattila P., Davies P., Wang D., Dickson D.W. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J. Neuropathol. Exp. Neurol. 2003, 62:389-397.
35. Vila M., Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat. Med. 2004, 10:S58-S62. (Suppl).
36. Huang Y., Cheung L., Rowe D., Halliday G. Genetic contributions to Parkinson's disease. Brain Res. Brain Res. Rev. 2004, 46:44-70.
37. Cookson M.R. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 2005, 74:29-52.
38. Oliveira S.A., Li Y.J., Noureddine M.A., Zuchner S., Qin X., Pericak-Vance M.A., Vance J.M. Identification of risk and age-at-onset genes on chromosome 1p in Parkinson's disease. Am. J. Hum. Genet. 2005, 77:252-264.
39. Khan N.L., Scherfler C., Graham E., Bhatia K.P., Quinn N., Lees A.J., Brooks D.J., Wood N.W., Piccini P. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 2005, 64:134-135.
40. Han F., Bulman D.E., Panisset M., Grimes D.A. Neuro-filament M gene in a French-Canadian population with Parkinson's disease. Can. J. Neurol. Sci. 2005, 32:68-70.
41. Perez-Olle R., Lopez-Toledano M.A., Liem R. The G336S variant in the human neurofilament-M gene does not affect its assembly or distribution: importance of the functional analysis of neurofilament varia. J. Neuropathol. Exp. Neurol. 2004, 63:759-774.
42. Rahner N., Holzmann C., Kruger R., Schols L., Berger K., Riess O. Neurofilament L gene is not a genetic factor of sporadic and familial Parkinson's disease. Brain Res. 2002, 951:82-86.
43. Kruger R., Fischer C., Schulte T., Strauss K.M., Muller T., Woitalla D., Berg D., Hungs M., Gobbele R., Berger K., Epplen J.T., Riess O., Schols L. Mutation analysis of the neuro-filament M gene in Parkinson's disease. Neurosci. Lett. 2003, 351:125-129.
44. Julien J.-P., Mushynski W.E. Neurofilaments in health and disease. Prog. Nucleic Acid Res. Mol. Biol. 1998, 61:1-23.
45. Ross C.A., Pickart C.M. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol. 2004, 14:703-711.
46. Benarroch E.E. Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system. Mayo Clin. Proc. 2005, 80(10):1326-1338.
47. Burke R.E. Postnatal developmental programmed cell death in dopamine neurons. Ann. NY Acad. Sci. 2003, 991:69-79.
48. Kuhn A.A., Hariz M.I., Silberstein P., Tisch S., Kupsch A., Schneider G.H., Limousin-Dowsey P., Yarrow K., Brown P. Activation of the subthalamic region during emotional processing in Parkinson's disease. Neurology 2005, 65:707-713.
49. Benabid A.L., Pollak P., Gross C., Hoffmann D., Benazzouz A., Gao D.M., Laurent A., Gentil M., Perret J. Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact. Funct. Neurosurg. 1994, 62:76-84.
50. Bejjani B.P., Damier P., Arnulf I., Thivard L., Bonnet A.M., Dormont D., Cornu P., Pidoux B., Samson Y., Agid Y. Transient acute depression induced by high frequency deep brain stim-ulation. N Engl. J. Med. 1999, 340:1476-1480.
51. Houeto J.L., Mesnage V., Mallet L., Pillon B., Gargiulo M., du Moncel S.T., Bonnet A.M., Pidoux B., Dormont D., Cornu P., Agid Y. Behavioral disorders, Parkinson's disease, and subthalamic stimulation. J. Neurol. Neurosurg. Psychiatry 2002, 72:701-707.
52. Funkiewiez A., Ardouin C., Caputo E., Krack P., Fraix V., Klinger H., Chabardes S., Foote K., Benabid A.L., Pollak P. Long term effects of bilateral subthalamic nucleus stimula-tion on cognitive function, mood, and behavior in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2004, 75:834-839.
53. Okun M.S., Raju D.V., Walter B.L., Juncos J.L., DeLong M.R., Heilman K., McDonald W.M., Vitek J.L. Pseudobulbar crying induced by stimulation in the region of the subthalamic nucleus. J. Neurol. Neurosurg. Psychiatry 2004, 75:921-923.
54. Krack P., Kumar R., Ardouin C., Dowsey P.L., McVicker J.M., Benabid A.L., Pollak P. Mirthful laughter induced by subthalamic nucleus stimulation. Mov. Disord. 2001, 16:867-875.
55. Romito L.M., Raja M., Daniele A., Contarino M.F., Bentivoglio A.R., Barbier A., Scerrati M., Albanese A. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov. Disord. 2002, 17:1371-1374.
56. Bejjani B.P., Houeto J.L., Hariz M., Yeinik J., Mesnage V., Bonnet A.M., Pidoux B., Dormont D., Cornu P., Agid Y. Aggressive behavior induced by intraoperative stimulation in the triangle of Sano. Neurology 2002, 59:1425-1427.
57. Berney A., Vingerhoets F., Perrin A., Guex P., Villemure J.G., Burkhard P.R., Benkelfat C., Ghika J. Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patient. Neurology 2002, 59:1427-1479.
58. Funkiewiez A., Ardouin C., Krack P., Fraix V., Van Blercom N., Xie J., Moro E., Benabid A.L., Pollak P. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov. Disord. 2003, 18:524-530.
59. Galvez-Jimenez N. Advances in the surgical treatment of Parkinson's disease: emphasis on pallidotomy and deep brain stimu- lation. Scientific Basis for the Treatment of Parkinson's Disease 2005, 151-168. Taylor & Francis, London. 2nd edition. N. Galvez-Jimenez (Ed.).
60. Lee M.S., Rinne J.O., Marsden C.D. The pedunculo-pontine nucleus: its role in the genesis of movement disorders. Yonsei Med. J. 2000, 41:167-184.
61. Bevan M.D., Bolam J.P. Cholinergic, GABAergic, and glutamate-enriched inputs from the mesopontine tegmentum to the subthalamic nucleus in the rat. J. Neurosci. 1995, 15:7105-7120.
62. Steiniger B., Kretschmer B.D. Glutamate and GABA modulate dopamine in the pedunculopontine tegmental nucleus. Exp. Brain Res. 2003, 149:422-430.
63. Pahapill P.A., Lozano A.M. The pedunculopontine nucleus and Parkinson's disease. Brain 2000, 123:1767-1783.
64. Scarnati E., Proia A., Di Loreto S., Pacitti C. The reciprocal electrophysiological influence between the nucleus tegmenti pedunculopontinus and the substantia nigra in normal and decorticated rats. Brain Res. 1987, 423:116-124.
65. Garcia-Rill E. The pedunculopontine nucleus. Progr. Neuro-biol. 1991, 36:363-389.
66. Olszewski J., Baxter D. Cytoarchitecture of the Human Brainstem 1954, Lippincott, Philadelphia.
67. Nutt J.G., Marsden C.D., Thompson P.D. Human walking and higher-level gait disorders, particularly in the elderly. Neurology 1993, 43:268-279.
68. Hanna J.P., Frank J.I. Automatic stepping in the pontomedullary stage of central herniation. Neurology 1995, 45:985-986.
69. Miller S., Scott P.D. Spinal generation of movement in a single limb: functional implications of a model based on the cat. Prog. Clin. Neurophysiol. 1980, 8:263-281.
70. Sohn Y.H., Hallett M. Basal ganglia, motor control and parkinsonism. The Scientific Basis for the Treatment of Parkinson's Disease 2005, 33-51. Taylor & Francis, London. 2nd edition. N. Galvez-Jimenez (Ed.).
71. Move- ment disorders. Handbook of Clinical Neurophysiology 2003, Vol. 1. Elsevier, Amsterdam. M. Hallett, J.R. Daube, F. Mauguuiere, (Eds.).
72. Rothwell J. Control of Human Voluntary Movement 1995, Chapman & Hall, London. 2nd edition.
73. Ceballos-Baumann A.O., Obeso J.A., Vitek J.L., Delong M.R., Bakay R., Linazasoro G., Brooks D.J. Restora-tion of thalamocortical activity after posteroventral pallidotomy in Parkinson's disease. Lancet 1994, 344:814.
74. Strafella A., Ashby P., Lozano A., Lang A.E. Palli-dotomy increases cortical inhibition in Parkinson's disease. Can. J. Neurol. Sci. 1997, 24:133-136.
75. Ren Y., Zhao J., Feng J. Parkin binds to α/β tubulin and increases their ubiquitination and degradation. J. Neurosci. 2003, 23:3316-3324.
76. The Human Nervous System 2004, NeuroScience Associates, Knoxville, TN. 2nd edition. G. Paxinos, J.K. Mai, (Eds.).
77. Shinotoh H., Namba H., Yamaguchi M., Fukushi K., Nagatsuka S., Iyo M., Asahina M., Hattori T., Tanada S., Irie T. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease a. Ann. Neurol. 1999, 46:62-69.
78. Masliah E., Alford M., Galasko D., Salmon D., Hansen L.A., Good P.F., Perl D.P., Thal L. Cholinergic deficits in the brains of patients with parkinsonism-dementia complex of Guam. Neuroreport 2001, 12:3901-3903.
79. Rinne J.O., Anichtchik O.V., Eriksson K.S., Kaslin J., Tuomisto L., Kalimo H., Roytta M., Panula P. Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy. J. Neurochem. 2002, 81:954-960.
80. Chazot P.L., Hann V. Overview: H3 histamine receptor isoforms: new therapeutic targets in the CNS?. Curr. Opin. Investig. Drugs 2001, 2:1428-1431.
81. Anichtchik O.V., Rinne J.O., Kalimo H., Panula P. An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp. Neurol. 2000, 163:20-30.
82. Anichtchik O.V., Peitsaro N., Rinne J.O., Kalimo H., Panula P. Distribution and modulation of histamine H3 receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson's disease. Neurobiol. Dis. 2001, 8:707-716.
83. Goodchild R.E., Court J.A., Hobson I., Piggott M.A., Perry R.H., Ince P., Jaros E., Perry E.K. Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's disease and Parkinson's disease cases. Eur. J. Neurosci. 1999, 11:440-456.
84. Terao A., Steininger T.L., Morairty S.R., Kilduff T.S. Age-related changes in histamine receptor mRNA levels in the mouse brain. Neurosci. Lett. 2004, 355:81-84.
85. Block G., Liss C., Reines S., Irr J., Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur. Neurol. 1997, 37:23-27.
86. Rascol O., Brooks D.J., Korczyn A.D., DeDeyn P.P., Clarke C.E., Lang A.E. A five-year study of the inci-dence of dyskinesias in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N. Engl. J. Med. 2000, 342:1484-1491.
87. Weiner W.J., Factor S.A. Ropinirole as compared with levodopa in Parkinson's disease. N. Engl. J. Med. 2000, 343:884-885.
88. The Parkinson Study Group. Levodopa and the progression of Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med. 2004, 351:2498-2508.
89. Hilker R., Portman A.T., Voges J., Staal M.J., Burghaus L., van Laar T., Koulousakis A., Maguire R.P., Pruim J., de Jong B.M., Herholz K., Sturm V., Heiss W.D., Leenders K.L. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J. Neurol. Neurosurg. Psychiatry 2005, 76:1217-1221.
90. Lim K.L., Dawson V.L., Dawson T.M. The cast of molecular characters in Parkinson's disease. felons, conspirators, and suspects. Ann. NY Acad. Sci. 2003, 991:80-92.
91. Modulation of movement by the basal ganglia. Neuroscience 2001, 391-407. Sunderland, Massachusetts. 2nd edition. D. Purves, G.J. Agustin, D. Fitzpatrick, L.C. Katz, A.S. LaMantina, J.O. McNamara, S.M. Williams, (Eds.).
92. Young A.B., Penney J.B. Biochemical and functional organization of the basal ganglia. Parkinson's Disease and Move- ment Disorders 2002, 1-10. Lippincott Williams & Wilkins, Philadelphia. 4th edition. J. Jankovic, E. Tolosa (Eds.).